PK/PD modelling and simulations: utility in drug development

被引:69
作者
Rajman, Iris [1 ]
机构
[1] Novartis Pharma AG, CH-4056 Basel, Switzerland
关键词
D O I
10.1016/j.drudis.2008.01.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation can be used as an 'applied science' tool to provide answers on efficacy and safety of new drugs faster and at a lower cost. PK/PD modelling can be used from the preclinical phase through all clinical phases of drug development. Optimal use of PK/PD modelling and simulation will lead to fewer failed compounds, fewer study failures and smaller numbers of studies needed for registration. For PK/PD modelling to fulfil its potential in drug development, it needs to be embraced across the industry and regulatory agencies, and more education on this topic is required.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 42 条
  • [1] Role of modelling and simulation in Phase I drug development
    Aarons, L
    Karlsson, MO
    Mentré, F
    Rombout, F
    Steimer, JL
    van Peer, A
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) : 115 - 122
  • [2] Mathematical models of targeted cancer therapy
    Abbott, L. H.
    Michor, F.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1136 - 1141
  • [3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [4] Clinical trial simulation in drug development
    Bonate, PL
    [J]. PHARMACEUTICAL RESEARCH, 2000, 17 (03) : 252 - 256
  • [5] Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
    Bueno, Lorea
    de Alwis, Dinesh P.
    Pitou, Celine
    Yingling, Jonathan
    Lahn, Michael
    Glatt, Sophie
    Troconiz, Inaki F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 142 - 150
  • [6] Modelling and simulation to improve decision-making in clinical development
    Burman, CF
    Hamrén, B
    Olsson, P
    [J]. PHARMACEUTICAL STATISTICS, 2005, 4 (01) : 47 - 58
  • [7] Interview - Raju Kucherlapati
    Carney, Steve
    Kucherlapati, Raju
    [J]. DRUG DISCOVERY TODAY, 2007, 12 (7-8) : 272 - 275
  • [8] Chaikin P, 2000, J CLIN PHARMACOL, V40, P1428
  • [9] Adaptive design in clinical research: Issues, opportunities, and recommendations
    Chang, Mark
    Chow, Shein-Chung
    Pong, Annpey
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (03) : 299 - 309
  • [10] Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation
    Chien, JY
    Friedrich, S
    Heathman, MA
    de Alwis, DP
    Sinha, V
    [J]. AAPS JOURNAL, 2005, 7 (03) : E544 - E559